Recombinant Human CD82 Protein

重组人CD82蛋白 | 重组人肿瘤转移抑制蛋白

CD82 antigenC33 | CD82 molecule | CD82 | IA4 | IA4C33 antigen | Inducible membrane protein R2 | KAI1 | KAI1GR15 | kangai 1 (suppression of tumorigenicity 6, prostate | CD82 antigen (R2 leukocyteantigen, antigen detected by monoclonal and IA4)) | Metastasi

rp188221-10μg

10μg

无动物源

≥95%(SDS-PAGE)

CD82, also known as KAI-1, structurally belongs to tetraspanin family while categorised as metastasis suppressor gene on functional grounds. KAI1/CD82 is localized on cell membrane and form interactions with other tetraspanins, integrins and chemokines which are respectively responsible for cell migration, adhesion and signalling. Downregulation of CD82 expression is associated with the advanced stages of many human cancers and correlates with the acquisition of metastatic potential. Recent studies suggest that complex mechanisms underlie CD82 loss of function, including altered transcriptional regulation, splice variant production and post-translational protein modifications, and indicate a central role for CD82 in controlling metastasis as a 'molecular facilitator'. The loss of KAI1/CD82 expression in invasive and metastatic cancers is due to a complex, epigenetic mechanism that probably involves transcription factors such as NFkappaB, p53, and beta-catenin. A loss of KAI1 expression is also associated with the advanced stages of many human malignancies and results in the acquisition of invasive and metastatic capabilities by tumour cells. Thus, KAI1/CD82 is regarded as a wide-spectrum tumor metastasis suppressor. Post-translational: Palmitoylated. Palmitoylation contributes to oligomerization and surface expression.

Testing in progress

重组表达

14.4 kDa

C-His

17.6-26.9 kDa, under reducing conditions; 17.6-26.9 kDa, under non-reducing conditions.

HEK293 Accession #: P27701 | HEK293

<1.0 EU/μg

人(Human)

111-228 aa

GKLKQEMGGIVTELIRDYNSSREDSLQDAWDYVQAQVKCCGWVSFYNWTDNAELMNRPEVTYPCSCEVKGEEDNSLSVRKGFCEAPGNRTQSGNHPEDWPVYQEGCMEKVQAWLQENLHHHHHH

Yes

Yes